CervoMed Inc. (NASDAQ: CRVO) presented new analyses from its Phase 2b RewinD‑LB trial at the AD/PD 2026 scientific conference in Copenhagen, Denmark, on March 19 2026. The data, released during an oral session, show that patients with lower plasma pTau181 levels—indicative of an earlier disease stage and absence of Alzheimer’s co‑pathology—experienced greater clinical benefit from neflamapimod.
The analyses demonstrate a stepwise increase in treatment effect across multiple clinical endpoints as plasma pTau181 levels decrease. In the highest enrichment group (pTau181 < 21 pg/mL), the mean change in the Clinical Dementia Rating Sum of Boxes (CDR‑SB) was –0.82 (p = 0.004) and the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS‑CGIC) score improved by –0.44 (p = 0.044). These results reinforce the company’s patient‑enrichment strategy and the planned Phase 3 trial design.
"The clinical and biomarker activity that we are seeing with neflamapimod provides a strong indication that we are successfully targeting the underlying cause of disease in the basal forebrain and supports our belief that the inhibition of p38α by neflamapimod can reverse the synaptic dysfunction that drives disease progression in ‘pure’ DLB patients," said Dr. John Alam, CEO of CervoMed. He added that the company is "very pleased to have achieved alignment with the FDA on key aspects of our Phase 3 design for neflamapimod in DLB, including our selected endpoints and patient enrichment strategy. This important feedback marks a major milestone for CervoMed, reinforcing our scientific approach and providing a regulatory pathway toward potential approval."
CervoMed plans to initiate a global Phase 3 trial in the second half of 2026, contingent on financing, and will use the 50 mg TID stable crystal form identified in earlier studies. The FDA alignment on endpoints and enrichment strategy gives the company a clear regulatory pathway for the Phase 3 study.
Financially, the company reported a Q4 2025 loss of $0.88 per share versus a consensus estimate of a $0.79 loss, and revenue of $0.01 million, missing analyst expectations by 98%. Net loss for the twelve months ended December 31 2025 was approximately $27.0 million, up from about $16.2 million in 2024. Grant revenue fell from $9.7 million in 2024 to $4.0 million in 2025. Cash and equivalents stood at $20.9 million as of December 31 2025, giving the company roughly six months of runway and underscoring the need for additional financing to fund the Phase 3 trial.
The positive clinical data bolster confidence in neflamapimod’s potential to slow disease progression in pure DLB, but the company’s limited cash position and recent earnings miss highlight significant financial headwinds. As a single‑asset, clinical‑stage biotech with no product sales, CervoMed’s future depends on securing the capital required to launch the Phase 3 study and on the continued success of the trial.
The presentation marks a significant milestone in the development of a first‑in‑class therapy for DLB, but the company’s financial constraints could delay the Phase 3 launch if financing is not secured in a timely manner.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.